Patents Assigned to XenoTherapeutics, Inc.
  • Publication number: 20240075186
    Abstract: A biological product for clinical xenotransplantation into a human and a method of preparing biological product for clinical xenotransplantation into a human involving producing a non-wild type, biologically engineered swine having a biologically engineered genome such that the swine does not express one or more extracellular surface glycan epitopes, is free of certain pathogens, is reared according to a bioburden-reducing procedure in a closed designated pathogen free herd, wherein the biological product is harvested following the swine being euthanized and the product is aseptically removed from the swine, the biological product is processed involving sterilization and storing the product in a sterile container, and the product does not contain one or more extracellular surface glycans, is free of certain designated pathogens, is biologically active and comprises live cells and tissues capable of vascularizing after xenotransplantation.
    Type: Application
    Filed: November 7, 2023
    Publication date: March 7, 2024
    Applicants: XENOTHERAPEUTICS, INC., ALEXIS BIO, INC.
    Inventors: Paul W. HOLZER, Jon ADKINS, Rodney L. MONROY, Elizabeth J. CHANG
  • Patent number: 11833270
    Abstract: A biological product for clinical xenotransplantation into a human and a method of preparing biological product for clinical xenotransplantation into a human involving producing a non-wild type, biologically engineered swine having a biologically engineered genome such that the swine does not express one or more extracellular surface glycan epitopes, is free of certain pathogens, is reared according to a bioburden-reducing procedure in a closed designated pathogen free herd, wherein the biological product is harvested following the swine being euthanized and the product is aseptically removed from the swine, the biological product is processed involving sterilization and storing the product in a sterile container, and the product does not contain one or more extracellular surface glycans, is free of certain designated pathogens, is biologically active and comprises live cells and tissues capable of vascularizing after xenotransplantation.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: December 5, 2023
    Assignee: XENOTHERAPEUTICS, INC.
    Inventors: Paul W. Holzer, Jon Adkins, Rodney L. Monroy, Elizabeth J. Chang
  • Publication number: 20230323400
    Abstract: A genetically reprogrammed, biologically active and metabolically active cell, tissue, and/or an organ comprising live cells that vascularize after xenotransplantation, wherein the genetically reprogrammed, biologically active and metabolically active cell, tissue, and/or an organ has been obtained from a non-wild type, biologically engineered porcine comprising a nuclear genome that has been reprogrammed to replace a plurality of nucleotides in a plurality of exon regions of a major histocompatibility complex of a wild-type porcine with a plurality of synthesized nucleotides from a human captured reference sequence, wherein the nuclear genome has wild-type porcine intron regions from a wild-type porcine and has been reprogrammed at exon regions.
    Type: Application
    Filed: February 22, 2023
    Publication date: October 12, 2023
    Applicants: Xenotherapeutics, Inc., Alexis Bio, Inc.
    Inventors: Paul W. HOLZER, Jon ADKINS, Rodney L. MONROY, Elizabeth J. CHANG, Kaitlyn ROGERS
  • Publication number: 20230274795
    Abstract: Predictive engineering of a sample derived from a genetically optimized non-human donor suitable for xenotransplantation into a human having improved quality or performance is described. A training data set is constructed from a series of libraries, including at least one library comprising genomic, proteomic, and research data specific to non-humans. A predictive machine learning model is developed based on the constructed training data set and utilized to obtain a predicted quality or performance of a plurality of sequences for a candidate sample from the non-human donor specific to a human patient or patient population. A subset of sequences is selected for evaluation from the plurality of sequences based on the predicted quality or performance and candidate samples are designed derived from the non-human donor using the selected subset of sequences.
    Type: Application
    Filed: November 30, 2022
    Publication date: August 31, 2023
    Applicants: XENOTHERAPEUTICS, INC., ALEXIS BIO, INC.
    Inventors: Paul HOLZER, Rodney MONROY, Andrey PTITSYN, Elizabeth CHANG, Jon ADKINS, Travis BROWN, Kaitlyn ROGERS
  • Publication number: 20230078894
    Abstract: A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically active and metabolically active, the biological system having genetically reprogrammed cells, tissues, and organs in a non-human animal for transplantation into a human recipient, wherein the non-human animal does not present one or more surface glycan epitopes and specific sequences from the wild-type swine's SLA is replaced with a synthetic nucleotides based on a human captured reference sequence from a human recipient's HLA.
    Type: Application
    Filed: October 14, 2022
    Publication date: March 16, 2023
    Applicants: XenoTherapeutics, Inc., Alexis Bio, Inc.
    Inventors: Paul W. HOLZER, Jon ADKINS, Rodney L. MONROY, Elizabeth J. CHANG
  • Publication number: 20220406409
    Abstract: A method for predictive engineering of a sample derived from a genetically optimized non-human donor suitable for xenotransplantation into a human having improved quality or performance is provided. The method includes constructing a training data set from a series of libraries, wherein at least one library in the series of libraries comprises genomic, proteomic, and research data specific to non-humans. The method includes developing a predictive machine learning model based on the constructed training data set. The method includes utilizing the predictive machine learning model to obtain a predicted quality or performance of a plurality of sequences for a candidate sample from the non-human donor specific to a human patient or patient population. The method includes selecting a subset of sequences for evaluation from the plurality of sequences based on the predicted quality or performance.
    Type: Application
    Filed: August 19, 2022
    Publication date: December 22, 2022
    Applicants: XENOTHERAPEUTICS, INC., ALEXIS BIO, INC.
    Inventors: Paul HOLZER, Rodney L. MONROY, Andrey PTITSYN, Elizabeth CHANG, Jon ADKINS, Travis BROWN, Kaitlyn ROGERS
  • Patent number: 11473062
    Abstract: A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically active and metabolically active, the biological system having genetically reprogrammed cells, tissues, and organs in a non-human animal for transplantation into a human recipient, wherein the non-human animal does not present one or more surface glycan epitopes and specific sequences from the wild-type swine's SLA is replaced with a synthetic nucleotides based on a human captured reference sequence from a human recipient's HLA.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: October 18, 2022
    Assignees: XenoTherapeutics, Inc., Alexis Bio, Inc.
    Inventors: Paul W. Holzer, Jon Adkins, Rodney L. Monroy, Elizabeth J. Chang
  • Patent number: 11424007
    Abstract: A method for predictive engineering of a sample derived from a genetically optimized non-human donor suitable for xenotransplantation into a human having improved quality or performance is provided. The method includes constructing a training data set from a series of libraries, wherein at least one library in the series of libraries comprises genomic, proteomic, and research data specific to non-humans. The method includes developing a predictive machine learning model based on the constructed training data set. The method includes utilizing the predictive machine learning model to obtain a predicted quality or performance of a plurality of sequences for a candidate sample from the non-human donor specific to a human patient or patient population. The method includes selecting a subset of sequences for evaluation from the plurality of sequences based on the predicted quality or performance.
    Type: Grant
    Filed: June 3, 2021
    Date of Patent: August 23, 2022
    Assignees: XENOTHERAPEUTICS, INC., ALEXIS BIO, INC.
    Inventors: Paul Holzer, Rodney L. Monroy, Andrey Ptitsyn, Elizabeth Chang, Jon Adkins, Travis Brown, Kaitlyn Rogers
  • Publication number: 20220053739
    Abstract: A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically and metabolically active (living), the biological system comprising genetically reprogrammed proteins, cells, tissues, and/or organs in a non-human animal donor for transplantation into a human recipient, wherein the non-human animal donor is a genetically reprogrammed porcine donor for xenotransplantation of cells, tissue, and/or an organ isolated from the genetically reprogrammed porcine donor.
    Type: Application
    Filed: August 24, 2021
    Publication date: February 24, 2022
    Applicants: XenoTherapeutics, Inc., XENOTHERAPEUTICS CORPORATION
    Inventors: Paul W. HOLZER, Jon ADKINS, Rodney L. MONROY, Elizabeth J. CHANG, Kaitlyn ROGERS
  • Publication number: 20220041996
    Abstract: A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically active and metabolically active, the biological system having genetically reprogrammed cells, tissues, and organs in a non-human animal for transplantation into a human recipient, wherein the non-human animal does not present one or more surface glycan epitopes and specific sequences from the wild-type swine's SLA is replaced with a synthetic nucleotides based on a human captured reference sequence from a human recipient's HLA.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Applicants: XenoTherapeutics, Inc., XenoTherapeutics Corporation
    Inventors: Paul W. HOLZER, Jon ADKINS, Rodney L. MONROY, Elizabeth J. CHANG
  • Publication number: 20210383892
    Abstract: A method for predictive engineering of a sample derived from a genetically optimized non-human donor suitable for xenotransplantation into a human having improved quality or performance is provided. The method includes constructing a training data set from a series of libraries, wherein at least one library in the series of libraries comprises genomic, proteomic, and research data specific to non-humans. The method includes developing a predictive machine learning model based on the constructed training data set. The method includes utilizing the predictive machine learning model to obtain a predicted quality or performance of a plurality of sequences for a candidate sample from the non-human donor specific to a human patient or patient population. The method includes selecting a subset of sequences for evaluation from the plurality of sequences based on the predicted quality or performance.
    Type: Application
    Filed: June 3, 2021
    Publication date: December 9, 2021
    Applicants: XENOTHERAPEUTICS, INC., XENOTHERAPEUTICS CORPORATION
    Inventors: Paul HOLZER, Rodney L. Monroy, Andrey PTITSYN, Elizabeth CHANG, Jon ADKINS, Travis BROWN, Kaitlyn ROGERS
  • Patent number: 11155788
    Abstract: A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically active and metabolically active, the biological system having genetically reprogrammed cells, tissues, and organs in a non-human animal for transplantation into a human recipient, wherein the non-human animal does not present one or more surface glycan epitopes and specific sequences from the wild-type swine's SLA is replaced with a synthetic nucleotides based on a human captured reference sequence from a human recipient's HLA.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: October 26, 2021
    Assignees: XenoTherapeutics, Inc., XenoTherapeutics Corporation
    Inventors: Paul W. Holzer, Jon Adkins, Rodney L. Monroy, Elizabeth J. Chang
  • Publication number: 20210308325
    Abstract: A biological product for clinical xenotransplantation into a human and a method of preparing biological product for clinical xenotransplantation into a human involving producing a non-wild type, biologically engineered swine having a biologically engineered genome such that the swine does not express one or more extracellular surface glycan epitopes, is free of certain pathogens, is reared according to a bioburden-reducing procedure in a closed designated pathogen free herd, wherein the biological product is harvested following the swine being euthanized and the product is aseptically removed from the swine, the biological product is processed involving sterilization and storing the product in a sterile container, and the product does not contain one or more extracellular surface glycans, is free of certain designated pathogens, is biologically active and comprises live cells and tissues capable of vascularizing after xenotransplantation.
    Type: Application
    Filed: June 14, 2021
    Publication date: October 7, 2021
    Applicants: XENOTHERAPEUTICS, INC., XENOTHERAPEUTICS CORPORATION
    Inventors: Paul W. HOLZER, Jon ADKINS, Rodney L. MONROY, Elizabeth J. CHANG
  • Patent number: 11129922
    Abstract: A biological product for clinical xenotransplantation into a human and a method of preparing biological product for clinical xenotransplantation into a human involving producing a non-wild type, biologically engineered swine having a biologically engineered genome such that the swine does not express one or more extracellular surface glycan epitopes, is free of certain pathogens, is reared according to a bioburden-reducing procedure in a closed designated pathogen free herd, wherein the biological product is harvested following the swine being euthanized and the product is aseptically removed from the swine, the biological product is processed involving sterilization and storing the product in a sterile container, and the product does not contain one or more extracellular surface glycans, is free of certain designated pathogens, is biologically active and comprises live cells and tissues capable of vascularizing after xenotransplantation.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: September 28, 2021
    Assignees: Xenotherapeutics, Inc., Xenotherapeutics Corporation
    Inventors: Paul W. Holzer, Jon Adkins, Rodney L. Monroy, Elizabeth J. Chang
  • Publication number: 20210238557
    Abstract: A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically active and metabolically active, the biological system having genetically reprogrammed cells, tissues, and organs in a non-human animal for transplantation into a human recipient, wherein the non-human animal does not present one or more surface glycan epitopes and specific sequences from the wild-type swine's SLA is replaced with a synthetic nucleotides based on a human captured reference sequence from a human recipient's HLA.
    Type: Application
    Filed: April 22, 2021
    Publication date: August 5, 2021
    Applicants: XenoTherapeutics, Inc., XenoTherapeutics Corporation
    Inventors: Paul W. HOLZER, Jon ADKINS, Rodney L. MONROY, Elizabeth J. CHANG
  • Patent number: 11028371
    Abstract: A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically active and metabolically active, the biological system having genetically reprogrammed cells, tissues, and organs in a non-human animal for transplantation into a human recipient, wherein the non-human animal does not present one or more surface glycan epitopes and specific sequences from the wild-type swine's SLA is replaced with a synthetic nucleotides based on a human captured reference sequence from a human recipient's HLA.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: June 8, 2021
    Assignees: Xenotherapeutics, Inc., Xenotherapeutics Corporation
    Inventors: Paul W. Holzer, Jon Adkins, Rodney L. Monroy, Elizabeth J. Chang
  • Publication number: 20210102176
    Abstract: A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically active and metabolically active, the biological system having genetically reprogrammed cells, tissues, and organs in a non-human animal for transplantation into a human recipient, wherein the non-human animal does not present one or more surface glycan epitopes and specific sequences from the wild-type swine's SLA is replaced with a synthetic nucleotides based on a human captured reference sequence from a human recipient's HLA.
    Type: Application
    Filed: October 26, 2020
    Publication date: April 8, 2021
    Applicants: XenoTherapeutics, Inc., XenoTherapeutics Corporation
    Inventors: Paul W. HOLZER, Jon ADKINS, Rodney L. MONROY, Elizabeth J. CHANG
  • Patent number: 10905799
    Abstract: A biological product for clinical xenotransplantation into a human and a method of preparing biological product for clinical xenotransplantation into a human involving producing a non-wild type, biologically engineered swine having a biologically engineered genome such that the swine does not express one or more extracellular surface glycan epitopes, is free of certain pathogens, is reared according to a bioburden-reducing procedure in a closed designated pathogen free herd, wherein the biological product is harvested following the swine being euthanized and the product is aseptically removed from the swine, the biological product is processed involving sterilization and storing the product in a sterile container, and the product does not contain one or more extracellular surface glycans, is free of certain designated pathogens, is biologically active and comprises live cells and tissues capable of vascularizing after xenotransplantation.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: February 2, 2021
    Assignees: Xenotherapeutics Corporation, Xenotherapeutics, Inc.
    Inventors: Paul W. Holzer, Jon Adkins, Rodney L. Monroy, Elizabeth J. Chang
  • Publication number: 20210001006
    Abstract: A biological product for clinical xenotransplantation into a human and a method of preparing biological product for clinical xenotransplantation into a human involving producing a non-wild type, biologically engineered swine having a biologically engineered genome such that the swine does not express one or more extracellular surface glycan epitopes, is free of certain pathogens, is reared according to a bioburden-reducing procedure in a closed designated pathogen free herd, wherein the biological product is harvested following the swine being euthanized and the product is aseptically removed from the swine, the biological product is processed involving sterilization and storing the product in a sterile container, and the product does not contain one or more extracellular surface glycans, is free of certain designated pathogens, is biologically active and comprises live cells and tissues capable of vascularizing after xenotransplantation.
    Type: Application
    Filed: September 10, 2020
    Publication date: January 7, 2021
    Applicants: XENOTHERAPEUTICS, INC., XENOTHERAPEUTICS CORPORATION
    Inventors: Paul W. HOLZER, Jon ADKINS, Rodney L. MONROY, Elizabeth J. CHANG
  • Patent number: 10883084
    Abstract: A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically active and metabolically active, the biological system having genetically reprogrammed cells, tissues, and organs in a non-human animal for transplantation into a human recipient, wherein the non-human animal does not present one or more surface glycan epitopes and specific sequences from the wild-type swine's SLA is replaced with a synthetic nucleotides based on a human captured reference sequence from a human recipient's HLA.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: January 5, 2021
    Assignees: XENOTHERAPEUTICS, INC., XENOTHERAPEUTICS CORPORATION
    Inventors: Paul W. Holzer, Jon Adkins, Rodney L. Monroy, Elizabeth J. Chang